Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Revenue (2019 - 2025)

Historic Revenue for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to $3.2 million.

  • Innate Pharma's Revenue fell 6447.19% to $3.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $81.4 million, marking a year-over-year decrease of 9983.93%. This contributed to the annual value of $21.5 million for FY2024, which is 6758.06% down from last year.
  • As of Q2 2025, Innate Pharma's Revenue stood at $3.2 million, which was down 6447.19% from $13.5 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Revenue registered a high of $50.6 billion during Q4 2022, and its lowest value of $3.2 million during Q2 2025.
  • Moreover, its 5-year median value for Revenue was $16.2 million (2021), whereas its average is $6.3 billion.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 36497413.0% in 2022, then tumbled by 9988.96% in 2023.
  • Quarter analysis of 5 years shows Innate Pharma's Revenue stood at $13.9 million in 2021, then soared by 364974.13% to $50.6 billion in 2022, then crashed by 99.89% to $55.8 million in 2023, then crashed by 75.85% to $13.5 million in 2024, then crashed by 76.48% to $3.2 million in 2025.
  • Its Revenue was $3.2 million in Q2 2025, compared to $13.5 million in Q4 2024 and $8.9 million in Q2 2024.